Watch for upcoming catalysts: brelovitug AZURE-4 data in Q4 2026, volixibat VANTAGE data in Q1 2027, and multiple regulatory submissions planned for H1 2027. The raised guidance and new product launch (ATEBRIOZ) provide near-term revenue visibility.
Drugs in focus
MIRM drug pipeline →brelovitug
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3 (completed)
- Time to market
- Mirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.
- Next catalyst
- BLA filing · H1 2027
What to watchBrelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $96.97entry
- T+1 · 12d ago −3.54%α +0.87% · $93.54
- T+5 · 6d ago −2.43%α −1.52% · $94.61
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7M, up 39.6% YoY, and raised full-year guidance to $715M-$720M. The company received FDA approval for ATEBRIOZ (zilurgisertib) in FOP and reported positive Phase 3 results for LIVMARLI and brelovitug. GAAP net loss was $40.8M ($0.62 per basic share), versus net income of $2.9M in Q3 2025.
Key Financial Metrics
Key Facts
- Q3 2026 net product sales $185.7M vs $133.0M YoY (+39.6%)
- 2026 net product sales guidance raised to $715M-$720M from $680M-$700M
- LIVMARLI sales $133.4M (+45% YoY); Bile Acid Medicines $52.3M (+28% YoY)
- FDA approved and launched ATEBRIOZ (zilurgisertib) for FOP
- LIVMARLI EXPAND Phase 3 met primary endpoint with statistical significance
- Brelovitug AZURE-1 Phase 3 in HDV met primary endpoint
- GAAP net loss $40.8M vs net income $2.9M in Q3 2025
- Cash and investments $500.5M as of Sep 30, 2026
- Repurchased $20M of convertible notes due 2029
Financial Impact
Q3 revenue beat consensus of $178.0M by $7.7M (+4.3%); full-year guidance raised by $15M-$20M at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| LIVMARLI | $133.4M | +45.0% |
| Bile Acid Medicines | $52.3M | +28.0% |
Risk Factors
- Company remains GAAP net loss-making with operating expenses growing faster than revenue
- Pipeline setbacks (volixibat NDA delay, brelovitug AZURE-4 results) could reset expectations
- Stockholders' deficit of $54.2M as of Sep 30, 2026 indicates accumulated losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759425-26-000061 |
| Document: mirm-20261103.htm | 0001759425-26-000061 |
| Document: 0001759425-26-000061-index-headers.html | 0001759425-26-000061 |
| Document: 0001759425-26-000061-index.html | 0001759425-26-000061 |
| Document: 0001759425-26-000061.txt | 0001759425-26-000061 |
| 8-K Data (Synthetic) | 0001759425-26-000061 |
Track record
27 reports on MIRM
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Viewing Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers